Trastuzumab for the treatment of HER2- positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction
Main Authors: | G Norman, S Rice, E Spackman, L Stirk, A Danso-Appiah, D Suh, S Palmer, A Eastwood |
---|---|
Format: | Article |
Language: | English |
Published: |
NIHR Journals Library
2011-05-01
|
Series: | Health Technology Assessment |
Online Access: | https://doi.org/10.3310/hta15suppl1/04 |
Similar Items
-
Oesophageal and gastro-oesophageal junction tumours
by: Bird-Lieberman, E, et al.
Published: (2007) -
The Evolution of Neo-Adjuvant Therapy in the Treatment of Oesophageal and Gastro-Oesophageal Junction Adenocarcinomas
by: Alexander A. Dermanis, et al.
Published: (2023-09-01) -
Serum HER 2 extracellular domain level is correlated with tissue HER 2 status in metastatic gastric or gastro-oesophageal junction adenocarcinoma.
by: Shu-Qin Dai, et al.
Published: (2013-01-01) -
HER2-positive disseminated gastric and gastro-oesophageal junction adenocarcinoma: forecast, clinical course, treatment
by: N S Besova
Published: (2014-09-01) -
Ramucirumab for advanced gastric cancer or gastro-oesophageal junction adenocarcinoma
by: Kate Young, et al.
Published: (2015-11-01)